Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Basic science

2774 - HORAS5 promotes cabazitaxel resistance in castration resistant prostate cancer via a BCL2A1-dependent survival mechanism

Date

29 Sep 2019

Session

Poster Discussion session - Basic science

Presenters

Perla Pucci

Citation

Annals of Oncology (2019) 30 (suppl_5): v797-v815. 10.1093/annonc/mdz269

Authors

P. Pucci1, E. Venalainen2, I. Alborelli3, L. Quagliata4, R. Mather5, S. Rigas5, I. Romero5, Y. Wang6, F. Crea5

Author affiliations

  • 1 Life Health And Chemical Sciences, The Open University, MK7 6BJ - Milton Keynes/GB
  • 2 Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver/CA
  • 3 Pathology, University Hospital Basel, 4031 - Basel/CH
  • 4 Pathology Department, Institute of Pathology-University Hospital Basel, 4031 - Basel/CH
  • 5 Life Health And Chemical Sciences, The Open University, MK7 6AA - Milton Keynes/GB
  • 6 Experimental Therapeutics, British Columbia Cancer Research Centre, Vancouver/CA

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2774

Background

Long non-coding RNAs (lncRNAs) have been recently identified as key players in several cancer-associated pathways such as metastasis and drug resistance. Emerging evidence indicates that the HORAS5 lncRNA (i.e. linc00161) modulates drug response in different malignancies. In a recently published study, we have shown that HORAS5 promotes the survival of androgen receptor-positive (AR+) castration resistant prostate cancer (CRPC) cells. Preliminary data obtained in our lab show that HORAS5 is involved in response to cabazitaxel, in both AR+ and AR- CRPC cells.

Methods

HORAS5 expression was modulated in AR+ and AR- CRPC cells with lentiviral-mediated overexpression and siRNA-based silencing. We measured cell count (Trypan Blue exclusion test) and apoptosis (caspase 3/7) of CRPC cells exposed to clinically achievable concentrations of cabazitaxel. RNA sequencing, RT-qPCR and western blot were used to identify genes regulated by HORAS5 in cabazitaxel-treated cells. We also transfected the cells with antisense oligonucleotides (ASOs), a technology that is currently being tested in clinical trials.

Results

Our results show that HORAS5 overexpression increases cabazitaxel IC50 (p = 0.01), while HORAS5 silencing has an opposite effect (p = 0.003). HORAS5 also inhibits caspase activity upon cabazitaxel treatment (p < 0.0001). RNA sequencing and RT-qPCR revealed that BCL2A1 is the most upregulated transcript in HORAS5 overexpressing cells exposed to cabazitaxel (p < 0.0001), and that BCL2A1 silencing decreases cell count (p < 0.03) and increases caspase activity (p < 0.0001). This evidence suggests that BCL2A1 expression is induced by HORAS5, thereby enhancing CRPC cells resistance to cabazitaxel. Transfection of CRPC cells with HORAS5-targeting ASOs can effectively silence this lncRNA (∼80% KD) and determine a decrease in the IC50 (p = 0.03) in response to cabazitaxel.

Conclusions

Our findings show that HORAS5 mediates cabazitaxel resistance in both AR+ and AR- CRPC cells via regulation of the anti-apoptotic BCL2A1. Experiments with ASOs demonstrate the translational potential of HORAS5 inhibition. We are currently assessing HORAS5 expression in biological fluids from patients exposed (or not) to cabazitaxel.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Francesco Crea.

Funding

The Open University.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.